Company: RCUS
Filing Date: 2025-10-28
Form Type: 10-Q
Source: 0001724521-25-000116
Chunk: 197

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-28
Form: 10-Q
Item: Part I, Item 1
Chunk 197
---
 (1)(1)Net loss—— (4)— (4)Balance at March 31, 202490.9 1,561 (853)(1)707 Issuance of common stock in connection with our equity award programs0.41 — — 1 Stock-based compensation—20 — — 20 Net loss—— (93)— (93)Balance at June 30, 202491.3 1,582 (946)(1)635 Issuance of common stock in connection with our equity award programs0.21 — — 1 Stock-based compensation—19 — — 19 Other comprehensive income—— — 2 2 Net loss—— (92)— (92)Balance at September 30, 202491.5$1,602 $(1,038)$1 $565 Balance at December 31, 202492.2$1,617 $(1,132)$— $485 Issuance of common stock (see Note 3, Related party - Gilead Sciences, Inc. and Note 13, Stockholders' equity)13.6142 — — 142 Issuance of common stock in connection with our equity award programs0.1— — — — Stock-based compensation—16 — — 16 Net loss—— (112)— (112)Balance at March 31, 2025105.91,775 (1,244)— 531 Issuance of common stock in connection with our equity award programs0.53 — — 3 Stock-based compensation—15 — — 15 Net income—— — — — Balance at June 30, 2025106.4 1,793 (1,244)— 549 Issuance of common stock (see Note 13, Stockholders' equity)0.78——8 Stock-based compensation—14— — 14 Net loss— — (135)— (135)Balance at September 30, 2025107.1$1,815 $(1,379)$— $436 

See accompanying notes.

4

ARCUS BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(unaudited)